9 unknown, 8 recruiting, 5 completed, 2 not yet recruiting. 15 Phase 2, 4 Phase 3, 3 Not applicable, 1 Phase 1, 1 Phase 4.
Follow Bevacizumab: new trials by email Literature Review of Bevacizumab trials Research Report on Bevacizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial Transarterial Chemoembolization (TACE), Hepatic Arterial Infusion Chemotherapy (HAIC, FOLFOX), Adebrelimab - Adebrelimab (SHR-1316), Bevacizumab | Phase 2 | Not yet recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 38 | 2026-04-10 | 2026-04-28 |
| Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases FSRT, HA-WBRT-SIB, Bevacizumab - Lung Adenocarcinoma, Brain Metastases | Phase 3 | Recruiting | Sun Yat-sen University | 220 | 2026-03-20 | 2026-04-06 |
| QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT Iparomlimab and Tuvonralimab Injection (QL1706), Bevacizumab, Hepatic Arterial Infusion Chemotherapy with Raltitrexed and Oxaliplatin (RALOX-HAIC) - Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin | Phase 2 | Recruiting | Nanfang Hospital, Southern Medical University | 38 | 2025-12-25 | 2026-01-13 |
| Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network Bevacizumab - Hereditary Hemorrhagic Telangiectasia (HHT), Pulmonary Hypertension | Enrolling by invitation | Poitiers University Hospital | 111 | 2025-10-15 | 2026-03-03 | |
| Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer Nivolumab, Bevacizumab, BMS-986340 - Microsatellite-stable Colorectal Cancer, Standard of Care | Phase 2 | Suspended | M.D. Anderson Cancer Center | 7 | 2025-08-15 | 2026-11-02 |
| Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC Trifluridine/tipiracil (TAS-102) plus bevacizumab - Colo-rectal Cancer, Third-line and Beyond Therapy | Phase 2 | Recruiting | Ruijin Hospital | 50 | 2025-08-01 | 2025-07-25 |
| Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study Iparomlimab and Tuvonralimab Injection plus Bevacizumab - PD-(L)1, CTLA-4 | Phase 4 | Not yet recruiting | Hebei Medical University Fourth Hospital | 40 | 2025-07-01 | 2025-06-04 |
| Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer Befotertinib combined Bevacizumab, Befotertinib combined platinum-based double chemotherapy - EGFR, Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Peng Zhang | 60 | 2024-11-07 | 2025-01-06 |
| dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma dTACE-HAIC - Advanced Hepatocellular Carcinoma, Atezolizumab | Not applicable | Recruiting | Sun Yat-sen University | 27 | 2024-10-01 | 2024-12-03 |
| Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer Eribulin, Bevacizumab - Breast Neoplasms, Neoplasm Metastasis | Phase 2 | Unknown | Wang Jiayu | 60 | 2024-08-01 | 2024-08-06 |
| Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases Cadonilimab, Bevacizumab, Cryoablation - Hepatocellular Carcinoma, Liver Cancer Stage IV | Not applicable | Recruiting | Sun Yat-sen University | 80 | 2024-02-02 | 2024-02-20 |
| Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma TACE with adebrelimab and bevacizumab - Adebrelimab, Hepatocellular Carcinoma | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 71 | 2023-11-15 | 2024-02-28 |
| XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine - Tislelizumab, Bevacizumab | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 52 | 2023-07-07 | 2023-08-01 |
| Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases Serplulimab combined with bevacizumab and first-line chemotherapy - Non-small Cell Lung Cancer Stage II, Bevacizumab | Phase 2 / Phase 3 | Completed | Sun Yat-sen University | 40 | 2023-05-14 | 2024-11-13 |
| Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy Bevacizumab+mFOLFOX6 - Neoadjuvant Treatment, Rectal Cancer | Phase 1 / Phase 2 | Unknown | Shanghai Minimally Invasive Surgery Center | 20 | 2022-11-01 | 2024-03-07 |
| Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer Albumin-bound paclitaxel and bevacizumab - Ovarian Carcinoma, Platinum-resistant Ovarian Cancer | Phase 2 | Unknown | Lei Li | 50 | 2022-03-27 | 2022-04-04 |
| Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation Bevacizumab, Icotinib - Carcinoma, Non-Small-Cell Lung, Bevacizumab | Phase 2 | Completed | Tianjin Medical University Cancer Institute and Hospital | 35 | 2022-01-30 | 2026-02-24 |
| The Effects of Preoperative Bevacizumab on Perioperative Complications Bevacizumab - Colorectal Cancer, Lung Cancer | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2021-04-01 | 2021-03-09 | |
| HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama Hepatic arterial infusion chemotherapy, Bevacizumab, Toripalimab - Hepatocellular Carcinoma, Bevacizumab | Phase 2 | Unknown | Sun Yat-sen University | 30 | 2021-01-01 | 2020-11-13 |
| Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma Locoregional therapy, Bevacizumab, Atezolizumab - Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody | Recruiting | Sun Yat-sen University | 240 | 2021-01-01 | 2025-08-14 |
Showing 20 of 26. Sign in to see all of them.
Carcinoma, Hepatocellular (5) · Brain Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (3) · Breast Neoplasms (2) · Liver Neoplasms (2) · Ovarian Neoplasms (2) · Adenocarcinoma of Lung (1) · Adnexal Diseases (1) · Carcinoma (1) · Carcinoma, Ovarian Epithelial (1) · Colonic Neoplasms (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1)
Neoplasms (19) · Neoplasms by Site (19) · Digestive System Diseases (10) · Digestive System Neoplasms (10) · Neoplasms by Histologic Type (7) · Neoplasms, Glandular and Epithelial (7) · Adenocarcinoma (6) · Carcinoma (6) · Lung Diseases (6) · Respiratory Tract Diseases (6) · Respiratory Tract Neoplasms (6) · Thoracic Neoplasms (6) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Intestinal Diseases (5)
Bevacizumab (19) · sintilimab (2) · toripalimab (2) · trifluridine tipiracil drug combination (2) · Albumin-Bound Paclitaxel (1) · Cryosurgery (1) · Folfox protocol (1) · Microscopic Angioscopy (1) · Nivolumab (1) · Oxaliplatin (1) · Pemetrexed (1) · Platinum (1) · Saline Solution (1) · Trifluridine (1) · atezolizumab (1)
Sun Yat-sen University (8) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Centre Georges Francois Leclerc (1) · Chulalongkorn University (1) · Hebei Medical University Fourth Hospital (1) · Lei Li (1) · LiNanlin,Ph.D, Chief Physician,Clinical Professor (1) · M.D. Anderson Cancer Center (1) · Nanfang Hospital, Southern Medical University (1) · Peng Zhang (1) · Poitiers University Hospital (1) · Ruijin Hospital (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Shanghai Minimally Invasive Surgery Center (1) · The First Affiliated Hospital of Xiamen University (1)
China (20) · France (2) · Thailand (1) · United States (1)
Fei Gao (1) · Feng Duan, MD (1) · Feng Lin (1) · Feng Ye (1) · Jiafei Chen (1) · Jianbo Chen (1) · Jiayu Wang, doctor (1) · Jinhua Huang, MD (1) · Jinzhang Chen, Study Director (1) · Kangshun Zhu, Professor (1) · Lei Li, M.D. (1) · Likun Chen, doctor (1) · Madhulika Eluri, MD (1)
PMID 15254054, PMID 16757720, PMID 16856022, PMID 19801201, PMID 23814264, PMID 25349290, PMID 26409291, PMID 27458945, PMID 29420112, PMID 29560093, PMID 30395902, PMID 31569068, PMID 32058845, PMID 32347302, PMID 33601296